Jensen Judd, Leonard Jan, Salottolo Kristin, McCarthy Kathryn, Wagner Jeffrey, Bar-Or David
Department of Neurology, Swedish Medical Center, Englewood, CO, USA.
Blue Sky Neurology, Englewood, CO, USA.
J Vasc Interv Neurol. 2018 Jun;10(1):32-38.
Vasoactive substances, including marijuana, are known precipitating factors of reversible cerebral vasoconstriction syndrome (RCVS). Our objective was to describe the demographics, suspected etiology, and outcomes of RCVS patients, with specific interest in examining the subset of patients who used marijuana prior to the onset of RCVS.
We identified and described consecutive RCVS cases treated at a regional, high-volume Comprehensive Stroke Center in Colorado (2012-2015). Univariate analyses were performed to examine the associations between the characteristics and outcomes (stroke and discharge disposition) of the RCVS patients by precipitating factors. We compared patients who used marijuana to those who did not and patients who used marijuana to patients who used vasoactive substances aside from marijuana.
Forty patients had RCVS. Sixteen (40%) cases were deemed idiopathic and 24 (60%) were secondary to a suspected trigger. Vasoactive substances were the most common suspected trigger ( = 18/24, 75%), 6 (33%) of which were marijuana. Approximately 80% of patients experienced an intracranial hemorrhage, 20% had an ischemic stroke, and yet 78% were discharged home. Patients with RCVS secondary to marijuana were more often male ( = 0.05) and younger ( = 0.02) compared to those who did not use marijuana; no differences were observed in the outcomes. These findings were consistent when examining marijuana versus other vasoactive substances.
This study suggests there are demographic differences between patients with RCVS triggered by marijuana compared to the typical RCVS patient. As more states legalize marijuana, medical conditions such as RCVS and their association with marijuana warrants further study and awareness.
血管活性物质,包括大麻,是已知的可逆性脑血管收缩综合征(RCVS)的诱发因素。我们的目的是描述RCVS患者的人口统计学特征、疑似病因和预后,特别关注检查在RCVS发病前使用过大麻的患者亚组。
我们识别并描述了在科罗拉多州一家区域大容量综合卒中中心接受治疗的连续RCVS病例(2012 - 2015年)。进行单因素分析以通过诱发因素检查RCVS患者的特征与预后(中风和出院处置)之间的关联。我们将使用过大麻的患者与未使用过大麻的患者进行比较,并将使用过大麻的患者与使用除大麻外的血管活性物质的患者进行比较。
40例患者患有RCVS。16例(40%)病例被认为是特发性的,24例(60%)继发于疑似诱因。血管活性物质是最常见的疑似诱因(24例中的18例,75%),其中6例(33%)是大麻。大约80%的患者发生了颅内出血,20%发生了缺血性中风,但仍有78%的患者出院回家。与未使用大麻的患者相比,继发于大麻的RCVS患者男性更多(P = 0.05)且更年轻(P = 0.02);在预后方面未观察到差异。在比较大麻与其他血管活性物质时,这些发现是一致的。
本研究表明,与典型的RCVS患者相比,由大麻引发的RCVS患者存在人口统计学差异。随着越来越多的州将大麻合法化,诸如RCVS等医学病症及其与大麻的关联值得进一步研究和关注。